Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131 [Yahoo! Finance]
Cellectar Biosciences, Inc. (CLRB)
Last cellectar biosciences, inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cellectar.com
Company Research
Source: Yahoo! Finance
iopofosine I 131 and the second is the review of the company's CLOVER WaM pivotal study of iopofosine I 131. The company will present these data at the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM) on Oct. 17, 2024, in Prague, Czech Republic. About Cellectar Biosciences' Iopofosine I 131 Iopofosine I 131 is a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether radioconjugate. The agent has demonstrated the ability to cross the blood-brain barrier with clinical activity in multiple hematologic malignancies that involve or occur within the central nervous system (CNS). This includes relapsed/refractory primary CNS lymphoma, which is most often the result of diffuse large B cell lymphoma infiltrating the CNS. More on Cellectar Biosciences' Presentation At IWWM, a case study report will be presented by Jorge Castillo MD, associate professor of medicine at Harvard Medical School and clinical director of Bing Center for Wal
Show less
Read more
Impact Snapshot
Event Time:
CLRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLRB alerts
High impacting Cellectar Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CLRB
News
- NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]Yahoo! Finance
- NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire
- Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
- Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate UpdateGlobeNewswire
CLRB
Earnings
- 11/18/24 - Miss
CLRB
Sec Filings
- 11/18/24 - Form 8-K
- 11/18/24 - Form 10-Q
- 11/15/24 - Form 8-K
- CLRB's page on the SEC website